touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)‘ (LBA17) was presented at the Virtual 2020 ESMO Congress, 12–21 September 2020.
- Why is triple-negative breast cancer so hard to treat, and what is the current standard of care for patients with metastatic disease? (0:15)
- Could you tell us a little about sacituzumab govitecan-hziy and its mechanism of action? (1:15)
- What were the aims and design of the ASCENT study? (2:48)
- What were the major efficacy and safety findings of the study? (3:29)
- How will these findings impact on clinical practice and what future studies are planned? (5:07)
Speaker Disclosures: Dr Aditya Bardia declares the following. Consultant/advisor for Biotheranostics, Daiichi Pharma/AstraZeneca, Genentech, Immunomedics, Lilly, Novartis, Pfizer, Puma Biotechnology, Merck, Philipps, Radius Health, Sanofi, Spectrum Pharmaceuticals, Foundation Medicine, and Taiho Pharmaceutical; research funding (to institution) from Biothernostics, Genentech/F. Hoffman-La Roche, Immunomedics, Innocrin Pharmaceuticals, Merck, Mersana Therapeutics, Novartis, Pfizer, Radius Health, and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. The ASCENT trial was sponsored by Immunomedics Inc.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Breast Cancer
Aditya Bardia, SABCS 2021: Results of EMERALD Phase III Trial
Dr Aditya Bardia (Harvard Medical School, Boston, MA, USA) discusses the results of the phase III EMERALD trial, exploring elacestrant, an oral selective estrogen receptor degrader, vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer following progression on prior endocrine and CDK4/6 inhibitor therapy. These results were presented at the San Antonio Breast […]
Nancy Lin, SABCS 2021: Updated Results of the HER2CLIMB Study
Dr Nancy Lin (Dana-Farber Cancer Institute, Boston, MA, USA) discusses the updated results of the phase II HER2CLIMB study, which assessed tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. […]
Marta Vaz Batista, SABCS 2021: Preliminary Results From the DEBBRAH Phase II Study
Dr Marta Vaz Batista (Hospital Fernando Fonseca, Amadora, Portugal) discusses the preliminary results from the DEBBRAH phase II study, exploring trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement. These results were presented at the San Antonio Breast Cancer Symposium 2021. Questions 1. Could you tell us a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!